Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 3:06 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1705–1728 of 2,102 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Injectable saline Clear all

Conditions: Atrial Fibrillation
Interventions: Botulinum Toxin Type A, Placebo; Drug
Lead sponsor: Joseph Mathew, M.D.; Other
Eligibility: 50 Years to 90 Years
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Type 1 Diabetes
Interventions: REMD-477, Placebo; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Osteoarthritis, Knee
Interventions: TissueGene-C, Normal Saline; Biological · Drug
Lead sponsor: Kolon TissueGene, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 5
States / cities: Pinellas Park, Florida • Baltimore, Maryland • Philadelphia, Pennsylvania + 2 more

Conditions: Healthy
Interventions: CD388 Injection, Saline placebo; Combination Product · Drug
Lead sponsor: Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years to 65 Years
Enrollment: 77 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Multiple Myeloma
Interventions: zoledronic acid; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 42
States / cities: Casa Grande, Arizona • La Verne, California • Los Angeles, California + 36 more

Conditions: SARS-CoV-2
Interventions: mRNA-1273, Placebo, mRNA-1273.222; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 12 Years to 18 Years
Enrollment: 4,328 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 48
States / cities: Banning, California • La Mesa, California • Lake Worth, Florida + 41 more

Conditions: COVID-19
Interventions: AS03, BNT162b2, BNT162b2 (B.1.1.529), BNT162b2 (B.1.351), BNT162b2 bivalent (wildtype and Omicron BA.1), BNT162b2 bivalent (wildtype and Omicron BA.4/BA.5), CoV2 preS dTM [B.1.351], CoV2 preS dTM/D614, CoV2 preS dTM/D614+B.1.351, mRNA-1273, mRNA-1273.351, mRNA-1273.529, mRNA-1273.617.2, Sodium Chloride, 0.9%; Drug · Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 1,270 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 22
States / cities: Birmingham, Alabama • San Diego, California • San Francisco, California + 15 more

Conditions: Melanoma
Interventions: dacarbazine plus Genasense, dacarbazine plus placebo; Drug
Lead sponsor: Genta Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 14
States / cities: Mobile, Alabama • Encinitas, California • Santa Rosa, California + 11 more

Conditions: Pelvic Cancer, Abdominal Cancer
Interventions: Omnipaque 300mg/mL Solution for Injection, Cone Beam CT, Radiation Therapy, 0.9% Saline; Drug · Radiation
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Lumbosacral Radicular Pain, Sciatic Radiculopathy, Sciatic Leg Pain, Sciatica, Lumbosacral Radicular Syndrome, Lumbosacral Radiculopathy
Interventions: C-1101, Placebo: Sterile Saline; Drug · Other
Lead sponsor: Consano Bio; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 3
States / cities: Fernandina Beach, Florida • Winston-Salem, North Carolina • Richmond, Virginia

Conditions: Opioid Use
Interventions: Bilateral abdominal Lap-TAP; Drug
Lead sponsor: Baylor Research Institute; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: COVID-19
Interventions: SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period), Placebo; Biological · Other
Lead sponsor: Novavax; Industry
Eligibility: 6 Months to 11 Years
Enrollment: 3,600 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 47
States / cities: Little Rock, Arkansas • Anaheim, California • Bellflower, California + 41 more

Conditions: Sars-CoV-2 Infection
Interventions: Peginterferon lambda alfa-1a subcutaneous injection, Saline; Drug · Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Wound; Abdomen, Abdominal Wall
Interventions: Botulinum Toxin Type A, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 2
States / cities: Rochester, Minnesota • Saint Paul, Minnesota

Conditions: Melanoma
Interventions: CP 870,893, Peptides, Oncovir poly IC:LC; Drug · Biological
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Osteoarthritis
Interventions: Dextrose Prolotherapy, Saline Prolotherapy, At-home physical therapy exercise group; Procedure · Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 40 Years to 70 Years
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2016
U.S. locations: 2
States / cities: Madison, Wisconsin

Conditions: Knee Osteoarthritis, Synovitis of Knee
Interventions: 4P004, Placebo (NaCl 0.9%); Drug
Lead sponsor: 4Moving Biotech; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 3
States / cities: Tucson, Arizona • Chicago, Illinois • Burlington, Massachusetts

Conditions: Chronic Exertional Compartment Syndrome
Interventions: Supervised Gait Retraining, Home Based Gait Retraining, Saline Injection, Botulinum Toxin Injection; Behavioral · Drug
Lead sponsor: Walter Reed National Military Medical Center; Federal
Eligibility: 18 Years to 50 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 4
States / cities: Bethesda, Maryland • Fort Bragg, North Carolina • Killeen, Texas + 1 more

Conditions: Moderate to Severe Glabellar Frown Lines
Interventions: IncobotulinumtoxinA (Xeomin) (20 Units), Placebo; Drug
Lead sponsor: Merz Pharmaceuticals GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 271 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 8
States / cities: Englewood, Colorado • Aventura, Florida • Coral Gables, Florida + 5 more

Conditions: Severe Hypertriglyceridemia
Interventions: Plozasiran Injection, Placebo; Drug
Lead sponsor: Arrowhead Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 311 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 50
States / cities: Birmingham, Alabama • Mobile, Alabama • Beverly Hills, California + 44 more

Conditions: Decision-Making, Patient Care, Treatment Decisions
Interventions: Influenza vaccine, Placebo; Biological · Other
Lead sponsor: University of Arkansas, Fayetteville; Other
Eligibility: 18 Years and older
Enrollment: 210 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 3
States / cities: Fayetteville, Arkansas • Albuquerque, New Mexico • Roanoke, Virginia

Conditions: Herpes Zoster, Varicella Zoster
Interventions: CRV 101, Placebo; Biological
Lead sponsor: Curevo Inc; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Dysphonia Resulting From Vocal Fold Scarring, Age-related Dysphonia
Interventions: Azficel-T (autologous fibroblasts), Placebo; Biological · Drug
Lead sponsor: Castle Creek Biosciences, LLC.; Industry
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 3
States / cities: Los Angeles, California • Stanford, California • New York, New York

Conditions: Healthy Volunteers
Interventions: GLA-AF, GLA-SE, Squalene; Drug · Other
Lead sponsor: Rockefeller University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Temporary Autonomic Blockade to Prevent Atrial Fibrillation After Cardiac Surgery

Effects of GRA in Patients With Type 1

Study of TG-C in Patients With Grade 3 Degenerative Joint Disease of the Knee

Study of CD388 Intramuscular or Subcutaneous Administration in Healthy Subjects

Zoledronic Acid Treatment (Every 4 or 12 Weeks) to Prevent Skeletal Complications in Advanced Multiple Myeloma Participants

A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19

COVID-19 Variant Immunologic Landscape Trial (COVAIL Trial)

Trial of Dacarbazine With or Without Genasense in Advanced Melanoma

IV Contrast-Enhanced Cone Beam Computed Tomography (CBCT) in Radiotherapy

Study to Evaluate Safety of C-1101 Versus Sterile Saline in Adults With Chronic Painful Lumbosacral Radiculopathy

Laparoscopic Transversus Abdominis Plane (TAP) Block to Reduce Post-operative Opioids

Study to Evaluate Safety and Immunogenicity of COVID-19 Vaccine in Children 6 Months to < 12 Years

Peginterferon Lambda-1a for the Prevention and Treatment of SARS-CoV-2 (COVID-19) Infection

The Biomechanical Effects of Flaccid Paralysis Induced by Botulinum Toxin a After Damage Control Laparotomy

Phase I Oncovir Poly IC:LC and NY-ESO-1/gp100

Joint Injections for Osteoarthritic Knee Pain

A Trial to Investigate the Safety and Efficacy of Intra-articular 4P004 Injection in Subjects With Knee Synovitis and Osteoarthritis

Comparison of Non-Surgical Treatment Options for Chronic Exertional Compartment Syndrome (CECS)

IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines

Study of Plozasiran in Adults With Severe Hypertriglyceridemia

Inflammation and Medical Provider Attitudes, Cognition, and Treatment Decisions Study

Safety, Tolerability, and Immunogenicity of CRV-101 in Healthy Adult Subjects

Controlled Study to Evaluate the Safety and Efficacy of Azficel-T for Vocal Fold Scarring and Age-Related Dysphonia

The Effects of GLA on Human Volunteers